Author

Santeri Artturi Pakola

Observed names: Pakola, Santeri, Pakola, Santeri A., Pakola, Santeri Artturi, S. Pakola, S.A. Pakola, Santeri A Pakola, Santeri A. Pakola, Santeri Pakola

Institution: University of Helsinki

Observed institutions: University of Helsinki, Helsinki University Hospital, Hospital District of Helsinki and Uusimaa

ORCID: 0000-0001-6235-8612

Observed ORCID: 0000-0001-6235-8612

OpenAlex ID: A5009672863

Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer

2022 · James H. A. Clubb, Tatiana V. Kudling, et al. · Frontiers in Immunology · 51

The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial

2025 · Matthew Stephen Block, James Hugo Armstrong Clubb, et al. · Nature Communications · 40

PDF

Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

2024 · Santeri A. Pakola, Katriina J. Peltola, et al. · Clinical Cancer Research · 37

PDF

Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression

2022 · Tatiana V. Kudling, James H.A. Clubb, et al. · OncoImmunology · 36

Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers

2021 · Joao Santos, Camilla Heiniö, et al. · Cells · 36

PDF

Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors

2024 · Elise Jirovec, Dafne C. A. Quixabeira, et al. · Journal of Experimental & Clinical Cancer Research · 28

PDF

Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer

2023 · Tatiana V. Kudling, James H.A. Clubb, et al. · OncoImmunology · 25

PDF

Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma

2025 · Tine J. Monberg, Santeri A. Pakola, et al. · Cell Reports Medicine · 23

Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine

2024 · Saru Basnet, Mirte Van der Heijden, et al. · Molecular Therapy · 23

Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors

2022 · Saru Basnet, Joao M. Santos, et al. · Molecular Therapy — Oncolytics · 16

Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer

2023 · D. C. A. Quixabeira, S. Pakola, et al. · Cancer Gene Therapy · 12

PDF

Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine

2023 · D. C. A. Quixabeira, E. Jirovec, et al. · Cancer Gene Therapy · 12

PDF

Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting

2023 · James H. A. Clubb, Tatiana V. Kudling, et al. · Frontiers in Immunology · 12

Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial

2025 · Santeri A Pakola, James H A Clubb, et al. · Journal for ImmunoTherapy of Cancer · 11

PDF

Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma

2024 · T.J. Monberg, T. Kudling, et al. · Immuno-Oncology Technology · 8

An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage

2023 · Santeri Pakola, Dafne C. A. Quixabeira, et al. · Frontiers in Immunology · 7

Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models

2025 · Santeri A. Pakola, Nea Ojala, et al. · Cancer Immunology Immunotherapy · 6

PDF

Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes

2025 · Tatiana V. Kudling, Dmitrii Bychkov, et al. · Cancer Gene Therapy · 6

Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma

2025 · Victor Arias, Tatiana V. Kudling, et al. · Molecular Therapy Oncology · 5

Dyslipidemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumors

2026 · James Hugo Armstrong Clubb, Santeri Artturi Pakola, et al. · Molecular Therapy · 3

PDF

Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors

2026 · Elise Jirovec, Katriina J. Jalkanen, et al. · Molecular Therapy · 2

514 Biomarker insights and long-term outcomes of TILT-123 oncolytic adenovirus combined with tumor-infiltrating lymphocytes in refractory metastatic melanoma: results from the TUNINTIL phase 1 trial

2025 · Tatiana V Kudling, Lyna Haybout, et al. · Journal for ImmunoTherapy of Cancer · 2

PDF

Neutralizing antibodies and lymphocyte count as biomarkers in patients receiving oncolytic adenovirus TILT-123 and adoptive cell transfer of tumor-infiltrating lymphocytes for metastatic melanoma refractory to immune checkpoint inhibitors.

2025 · Lyna Haybout, James Clubb, et al. · Journal of Clinical Oncology · 2

Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine

2024 · Saru Basnet, Mirte Van der Heijden, et al. · Molecular Therapy · 2

PDF

PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.

2024 · Joao Manuel Santos, Matthew Stephen Block, et al. · Journal of Clinical Oncology · 2

Works count: 80

Citation count: 408

H-index: 12

I10-index: 14